GlaxoSmithKline and Gilead to face off at HIV meeting next week

File photo of a GlaxoSmithKline logo outside one of its buildings in west LondonBy Ben Hirschler LONDON (Reuters) – GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle. Most attention is focused on Gilead's next-generation drug bictegravir, a so-called integrase inhibitor similar to GSK's successful dolutegravir that may offer advantages in terms of greater potency and reduced side effects. As dolutegravir has been the mainstay of GSK's HIV business in recent years, investors are nervous about the threat posed by Gilead's competitor, even though next week's bictegravir data is only from mid-stage Phase II testing.

Sexual Health News Headlines – Yahoo! News